Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

More Must-Hear News From Biopharma

Executive Summary

Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020.

You may also be interested in...



UK Biotechs Seek Government Help As Economic ‘Heart Attack’ Threatens Sector

Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.

Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up

The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.

Spanish Biotechs Join Battle Against COVID-19

Spain has suffered more than most from COVID-19 but the life sciences sector is exploring a variety of ways to tackle the coronavirus pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141703

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel